Enter your email address:

Delivered by FeedBurner

GSK, Vir Biotech to expand COVID-19 research partnership for other diseases

As a part of the deal to research and develop monoclonal antibody
treatments for influenza and other respiratory illnesses, GSK will
make a further $120 million equity investment in Vir and an additional
upfront payment of $225 million.


vivitide said...
October 8, 2021 at 1:39 AM  

Mostly I do not comment on any post, but your blog has lots of knowledge about Custom Peptide Synthesis Services Online. It's forcing me to do this. It has really amazing content. Please share more information with us.

Post a Comment